These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17184394)

  • 21. Potential Future Use, Costs, and Value of Poliovirus Vaccines.
    Thompson KM; Kalkowska DA
    Risk Anal; 2021 Feb; 41(2):349-363. PubMed ID: 32645244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology of poliomyelitis--options and update.
    Dutta A
    Vaccine; 2008 Oct; 26(45):5767-73. PubMed ID: 18755232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Universal use of inactivated poliovirus vaccine--the needs and challenges].
    Shimizu H; Takeda N
    Nihon Rinsho; 2008 Oct; 66(10):1950-5. PubMed ID: 18939495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization.
    Khan MM; Sharma S; Tripathi B; Alvarez FP
    Public Health; 2017 Jan; 142():31-38. PubMed ID: 28057194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Worldwide eradication of poliomyelitis].
    Rasch G; Schreier E; Kiehl W; Kurth R
    Wien Klin Wochenschr; 2001 Oct; 113(20-21):839-45. PubMed ID: 11732120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrospective cost-effectiveness analyses for polio vaccination in the United States.
    Thompson KM; Tebbens RJ
    Risk Anal; 2006 Dec; 26(6):1423-40. PubMed ID: 17184390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global surveillance and the value of information: the case of the global polio laboratory network.
    de Gourville E; Duintjer Tebbens RJ; Sangrujee N; Pallansch MA; Thompson KM
    Risk Anal; 2006 Dec; 26(6):1557-69. PubMed ID: 17184397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The perspective of global eradication of poliomyelitis].
    Knolle H; Egli A; Candrian U
    Gesundheitswesen; 2004 Jan; 66(1):1-6. PubMed ID: 14767784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case for developing antiviral drugs against polio.
    Collett MS; Neyts J; Modlin JF
    Antiviral Res; 2008 Sep; 79(3):179-87. PubMed ID: 18513807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox.
    Heinsbroek E; Ruitenberg EJ
    Vaccine; 2010 May; 28(22):3778-83. PubMed ID: 20362626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Policy decision options during the first 5 years following certification of polio eradication.
    Sangrujee N; Duintjer Tebbens RJ; Cáceres VM; Thompson KM
    MedGenMed; 2003 Dec; 5(4):35. PubMed ID: 14745382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inactivated Polio Vaccine (IPV): a strong candidate vaccine for achieving global polio eradication program.
    Shahzad A; Köhler G
    Vaccine; 2009 Aug; 27(39):5293-4. PubMed ID: 19638271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of house-to-house versus fixed-site oral poliovirus vaccine delivery strategies in a mass immunization campaign in Egypt.
    Linkins RW; Mansour E; Wassif O; Hassan MH; Patriarca PA
    Bull World Health Organ; 1995; 73(5):589-95. PubMed ID: 8846484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission.
    Aylward RB; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):40-6. PubMed ID: 15106299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management.
    Duintjer Tebbens RJ; Pallansch MA; Kew OM; Sutter RW; Bruce Aylward R; Watkins M; Gary H; Alexander J; Jafari H; Cochi SL; Thompson KM
    Risk Anal; 2008 Aug; 28(4):855-76. PubMed ID: 18627544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The golden jubilee of vaccination against poliomyelitis.
    John TJ
    Indian J Med Res; 2004 Jan; 119(1):1-17. PubMed ID: 14997988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule.
    Miller MA; Sutter RW; Strebel PM; Hadler SC
    JAMA; 1996 Sep; 276(12):967-71. PubMed ID: 8805731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.
    Thompson KM; Duintjer Tebbens RJ
    Expert Rev Vaccines; 2014 Feb; 13(2):221-34. PubMed ID: 24308581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating vaccine-derived polioviruses: current state of knowledge.
    Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
    Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.